Microfluidic Chip for Blood-Tissue Barrier Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in-vitro models for the blood-brain barrier and blood-tumor barrier lack physiological relevance due to their static nature and limited fluid flow, making them inadequate for accurate drug testing and screenings, and are difficult to use for studying cell reactions to different treatments.
Innovation Solution
A multi-layer microfluidic chip with removably attached layers, including a lumen with inlet and outlet ports, porous barrier layers, and separate chambers for culturing endothelial and brain or tumor cells, allowing for fluid communication and high-throughput drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Transwell plates are used to mimic endothelial cell interactions, then the model is simple and easy to manufacture, but the model lacks physiological relevance due to its static nature and lack of fluid flow
Solution Approach 1:
The patent transforms the static Transwell plate into a dynamic microfluidic system by introducing fluid flow through channels. The microfluidic chip enables controlled circulation of media through the endothelial cell layer, allowing the system to dynamically adapt to physiological conditions while maintaining ease of manufacture through standardized microfabrication processes.
Solution Approach 2:
The patent incorporates hydraulic principles by implementing fluid flow through microfluidic channels to simulate blood flow conditions. The system uses pressure-driven or pump-driven fluid circulation to create physiologically relevant flow patterns across the endothelial barrier, enhancing the model's reliability while keeping the manufacturing process accessible.
2Reliability
If microfluidic chips are used to provide fluid flow and physiological relevance, then the model becomes more realistic, but establishing cell colonies becomes very difficult and time-consuming
Solution Approach 1:
The patent employs preliminary action by pre-coating the microfluidic channels and chambers with extracellular matrix proteins or adhesive agents before cell seeding. This pre-preparation facilitates rapid cell attachment and colony formation, reducing the time required to establish physiological models while maintaining the fluid flow advantages of microfluidic systems.
Solution Approach 2:
The patent utilizes parameter changes by optimizing flow rates, media composition, and chamber dimensions to create conditions that accelerate cell proliferation and barrier formation. By adjusting these parameters, the system achieves rapid establishment of functional cell colonies without compromising the physiological relevance provided by fluid flow.
3Stability of the object's composition
If sealed microfluidic systems are used to maintain controlled environments, then the model provides stable conditions, but cells become inaccessible for research and treatment testing
Solution Approach 1:
The patent applies segmentation by dividing the microfluidic system into modular compartments and chambers. This allows the endothelial barrier to remain sealed and stable in certain regions while providing accessible windows or interfaces in other regions where cells can be selectively accessed for research purposes without compromising the overall environmental stability of the system.
Solution Approach 2:
The patent introduces intermediary structures such as permeable membranes or controlled access ports that allow researchers to interact with cells in the sealed microfluidic environment. These intermediaries enable treatment delivery and cell analysis while maintaining the stable, controlled conditions necessary for physiological relevance.
4Reliability
If current microfluidic chips are used for drug screening, then the model provides physiological relevance, but it is single throughput making it unrealistic for high-volume drug testing
Solution Approach 1:
The patent merges multiple functional elements into an integrated microfluidic platform that combines physiological relevance with high throughput capability. By integrating multiple chambers, flow paths, and detection systems into a single device, the system enables parallel processing of multiple drug candidates while maintaining controlled physiological conditions across all test sites.
Solution Approach 2:
The patent designs a universal microfluidic platform that can accommodate various cell types, barrier models, and drug screening applications within a single system architecture. This multi-functional design allows the same device to perform different throughput levels and experimental configurations, making it adaptable to both high-volume drug testing and detailed physiological studies.
5Ease of manufacture
If poly-di-methyl-siloxane is used to manufacture microfluidic chambers, then the manufacturing process is simple, but the material binds certain drug types limiting its use in drug discovery
Solution Approach 1:
The patent applies local quality by using different materials for different components of the microfluidic system. While poly-di-methyl-siloxane may be used for certain chambers due to its manufacturing advantages, other components such as channel walls, barrier layers, and drug contact surfaces are made from drug-compatible materials like PDMS-free polymers or glass, ensuring chemical inertness and drug compatibility throughout the system.
Solution Approach 2:
The patent employs composite material structures that combine the manufacturing advantages of silicone-based materials with drug-compatible polymers. The microfluidic device integrates multiple material layers with different properties, allowing easy manufacturing in certain regions while ensuring drug compatibility in regions where drugs contact the material, thus resolving the contradiction between manufacturing simplicity and drug versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microfluidic chip provides a more physiologically relevant model for drug testing, enabling accurate drug screening and understanding of drug transport across the blood-brain and blood-tumor barriers, with improved accessibility for cell research and higher throughput capabilities.
Implementation Method 1
one or more porous barrier layers, wherein the one or more porous barrier layers contain pores with a size ranging from about 2 μm to about 3 μm
Data Source
AI summary
A microfluidic device is useful for modelling drug transmission across the vasculature and vascular barriers. The device includes a frame, a fluid-permeable lumen configured to carry a fluid through the frame in a first direction, a first chamber surrounding the lumen, and a second chamber surrounding the first fluid-permeable chamber. At least one surface of the first chamber is configured for deposition of a first population of endothelial cells. An outer surface of the second chamber is configured for deposition a second population of cells. The second chamber is configured to carry a fluid through the frame in a second direction. The fluid-permeable lumen is configured to allow the fluid to permeate through a wall of the lumen into the first chamber, and the first chamber and the second chamber are in fluid communication with each other.